300 related articles for article (PubMed ID: 16636344)
1. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
[TBL] [Abstract][Full Text] [Related]
3. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Fujita K; Ando Y; Nagashima F; Yamamoto W; Eodo H; Araki K; Kodama K; Miya T; Narabayashi M; Sasaki Y
Cancer Chemother Pharmacol; 2007 Sep; 60(4):515-22. PubMed ID: 17406868
[TBL] [Abstract][Full Text] [Related]
4. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
5. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
[TBL] [Abstract][Full Text] [Related]
6. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Nakamura Y; Soda H; Oka M; Kinoshita A; Fukuda M; Fukuda M; Takatani H; Nagashima S; Soejima Y; Kasai T; Nakatomi K; Masuda N; Tsukamoto K; Kohno S
J Thorac Oncol; 2011 Jan; 6(1):121-7. PubMed ID: 21150467
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
9. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
10. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
13. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
[TBL] [Abstract][Full Text] [Related]
15. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
[TBL] [Abstract][Full Text] [Related]
16. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
Tsunedomi R; Hazama S; Fujita Y; Okayama N; Kanekiyo S; Inoue Y; Yoshino S; Yamasaki T; Suehiro Y; Oba K; Mishima H; Sakamoto J; Hamamoto Y; Oka M
Int J Oncol; 2014 Oct; 45(4):1381-90. PubMed ID: 25175642
[TBL] [Abstract][Full Text] [Related]
17. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
19. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
Yamamoto N; Takahashi T; Kunikane H; Masuda N; Eguchi K; Shibuya M; Takeda Y; Isobe H; Ogura T; Yokoyama A; Watanabe K
Clin Pharmacol Ther; 2009 Feb; 85(2):149-54. PubMed ID: 18685565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
